NCT07083115
Developing MRI Technologies for Atrial Fibrillation
Enrolling by Invitation
Not specifiedAges 18+ObservationalThe Cleveland ClinicInvestigator-initiated
~50 participants
Updated 2026-03-23 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Image quality
Measured over At completion of each MRI
Conditions
Where it's being run
1 sites across 1 statesOhio1
Study leadership
- Christopher Nguyen, PhD · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Diagnosis of Atrial Fibrillation
Exclusion
Contraindications to MRI
Contraindications to Gadolinium based contrast agents.
What this trial measures
- Image qualityAt completion of each MRI
To demonstrate standard dose (0.05mmol/kg) of Gadopiclenol cardiac MRI significantly improves the enhancement of AF compared with standard dose (0.1mmol/kg) of conventional GBCA agents. Research MRI data will be reviewed against any standard clinical MRI available in the patient's medical record.